EQL Pharma AB (EQL) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of EQL Pharma AB SEK 9.34, price SEK 23.00, upside -59.4%, quality 32 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch EQL Pharma AB for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
EQL Pharma AB (publ) engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe. It offers injection products for inpatient care and formulations for outpatient care. EQL Pharma AB (publ) was incorporated in 2006 and is based in Lund, Sweden.
Stock analysis
EQL Pharma AB (EQL) currently trades at kr 23.00, while our model-based Fair Value estimate is kr 9.34, implying the stock looks roughly 146.2% overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of kr 10.65 per share, and 0 of the 14 models we run sit above the kr 23.00 price.
Bear case: the Economic Profit group reads lowest at kr 1.67, and 14 of the 14 models stay below the price. Evidence for this calculation is low.
Scenario range: kr 7.01 (bear) to kr 13.85 (bull), the price of kr 23.00 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 32/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
EQL Pharma AB reported revenue of 433M SEK in FY2026 versus 410M SEK in FY2022, a compound +1.4%/yr. Reported net income was 12.5M SEK in FY2026, compounding −20.6%/yr from FY2022.
Key figures
Market cap 679M SEK (≈ $68.5M) · P/E ratio 54.2 · P/S ratio 1.57 · EPS (TTM) kr 0.4246 · Net margin 2.9% · Return on equity −1.1% · Return on assets (EBIT) 10.7% · Operating margin −16.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 47 out of 100 (low confidence).
What moves the price
The share trades about 67% below its 52-week high and 17% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at −59%, EQL screens richer than that median.
Fair Value models
Bear kr 7.01Fair Value kr 9.34Bull kr 13.85
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (kr 0.2048 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.58/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+15.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.3%
Start year 2021 (pandemic)
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis.
+14.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year+14.0%
Dividend (yield on the price)0.0%
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.6% → 11%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 629 stocks
Beats the industry median on 2/10 measures
Overall it trails its industry peers.
Valuation
Quality Score32 · Bottom 25%
Fair Value upside−59% · Bottom 25%
Profitability
Return on assets−1% · Below median
Net margin (TTM)−2% · Below median
Operating margin (TTM)−17% · Bottom 25%
Growth and dividend
Revenue growth21% · Top 25%
Balance sheet
Debt / equity1.29× · Highest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (TTM)54.2× · Priciest 25%
P/B0.26× · Cheapest 25%
P/S (TTM)2.15× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 15
FUTURE (revenue growth)100· sector 20
PAST (return on equity)0· sector 27
HEALTH (low debt)35· sector 96
DIVIDEND (yield)0· sector 32
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "EQL Pharma AB Fair Value". https://www.fairvalue-calculator.com/stock/EQL
Frequently asked questions
Is EQL Pharma AB (EQL) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of kr 9.34 versus a price of kr 23.00, about −59% upside (overvalued).
What is the fair value of EQL?
Our model-based fair value for EQL Pharma AB is kr 9.34 (as of Sep 24, 2026), built from audited fundamentals. The current price: kr 23.00.
What is the quality score of EQL?
EQL Pharma AB has a Quality Score of 32/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for EQL Pharma AB (EQL)?
Our model-based price target is the fair value of kr 9.34 (as of Sep 24, 2026) from 14 valuation models. Cautious scenario kr 7.01, optimistic scenario kr 13.85. It is a calculation from audited fundamentals, not an analyst target.
What is the EQL Pharma AB stock forecast for 2026?
Our models put fair value at kr 9.34, about −59% upside versus a price of kr 23.00 (overvalued). Cautious scenario kr 7.01, optimistic scenario kr 13.85. The calculation is refreshed regularly with new filings.
What is the intrinsic value of EQL Pharma AB (EQL)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For EQL Pharma AB it is kr 9.34 per share (as of Sep 24, 2026), against a price of kr 23.00. It is the blended result of 14 valuation models (cash flow, earnings, asset, dividend).
Is EQL Pharma AB stock overvalued or undervalued in 2026?
As of Sep 24, 2026, EQL trades above its calculated fair value: price kr 23.00, fair value kr 9.34, a gap of about −59% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of EQL?
No. The price is what the market pays today (kr 23.00); the fair value is what the company's own numbers justify (kr 9.34). For EQL Pharma AB the two are kr 13.66 per share apart. That gap is exactly why we show both numbers side by side.
How much is EQL Pharma AB worth?
The market values EQL Pharma AB at about 679M SEK (market capitalisation, as of Sep 24, 2026). Per share that is kr 23.00; our models calculate a fair value of kr 9.34 per share.
What do the bullish and bearish scenarios say about EQL?
Our models span a range for EQL Pharma AB: cautious scenario kr 7.01, base kr 9.34, optimistic kr 13.85 per share (as of Sep 24, 2026, price kr 23.00). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of EQL?
EQL Pharma AB trades at a price-to-earnings ratio of 54.2 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of kr 9.34 is built from several models across several years. Other multiples: P/B 0.3, P/S 2.1.
How solid is the balance sheet of EQL Pharma AB (EQL)?
Balance-sheet figures for EQL Pharma AB (as of Sep 24, 2026): return on equity −1.1%, debt of 1.29 per unit of equity. They feed the Quality Score of 32/100, which measures business quality independently of the share price.
How far is EQL from its 52-week high?
EQL Pharma AB trades at kr 23.00, about 67% below its 52-week high of kr 69.90 and 17% above the low of kr 19.72 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of kr 9.34 is for.
Which stocks are comparable to EQL Pharma AB?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is EQL Pharma AB stock attractive at the current price?
The data as of Sep 24, 2026: price kr 23.00, calculated fair value kr 9.34 (−59%), Quality Score 32/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of EQL calculated?
We run EQL Pharma AB through 14 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 9.34, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. EQL Pharma AB itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of EQL Pharma AB (EQL)?
The closing price on Sep 24, 2026 was kr 23.00. Our model-based fair value is kr 9.34, about −59% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with EQL Pharma AB right now?
The price sits above even our optimistic bull case (kr 13.85). The favourable scenario is already priced in. Weak quality (32/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (kr 7.01 to kr 13.85) leaves room in how you read the outcome.
Key figures of EQL Pharma AB
How large is the market capitalisation of EQL Pharma AB (EQL)?
The market capitalisation of EQL Pharma AB is 679M SEK (≈ $68.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of EQL Pharma AB (EQL)?
The price-to-sales ratio of EQL Pharma AB is 1.57 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of EQL Pharma AB (EQL)?
Earnings per share at EQL Pharma AB are kr 0.4246 (price ÷ EPS = P/E 54.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of EQL Pharma AB (EQL)?
The net margin of EQL Pharma AB is 2.9% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of EQL Pharma AB (EQL)?
The return on equity (ROE) of EQL Pharma AB is −1.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of EQL Pharma AB (EQL)?
On an EBIT basis the return on assets of EQL Pharma AB is 10.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of EQL Pharma AB (EQL)?
The operating margin of EQL Pharma AB is −16.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at EQL Pharma AB (EQL)?
Revenue at EQL Pharma AB is growing +21.3% versus a year earlier (3y avg +18.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at EQL Pharma AB (EQL)?
Earnings per share at EQL Pharma AB are growing −2.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does EQL Pharma AB (EQL) generate?
The free cash flow of EQL Pharma AB is −38.9M SEK (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does EQL Pharma AB (EQL) carry?
The net debt of EQL Pharma AB is 398M SEK (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch EQL Pharma AB in the live analysis
One click puts EQL Pharma AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
